Cancer specific vaccine therapy using HLA-A24 restricted epitope-peptide for patients with advanced metastatic colorectal cancer.PhaseI/II clinical trial.
Phase 1
- Conditions
- colorectal cancer
- Registration Number
- JPRN-UMIN000004994
- Lead Sponsor
- Hokkaido Cancer Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1 Expectant 2 During lactation 3 possible expectant women 4 Active infectious diseases 5 Systemic use of steroid hormones or immunosuppressive drugs 6 Others (Doctors judges)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method